Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Walmsley

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
The AIDS Reader|July 4, 2003
Individualized therapy for the treatment-experienced patientSharon Walmsley
Current Opinion in HIV and AIDS|April 18, 2009
Combining protease inhibitors with new drug classes in treatment-experienced patientsSharon Walmsley
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|February 1, 2013
The clinical cost of delays in switching therapySharon Walmsley
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2007
Protease inhibitor-based regimens for HIV therapy: safety and efficacySharon Walmsley
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 27, 2009
Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor classTroy Grennan, Sharon Walmsley
Current Opinion in HIV and AIDS|January 6, 2010
First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approachIsaac Bogoch, Sharon Walmsley
Current Infectious Disease Reports|June 13, 2012
CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and managementLisa Barrett, Sharon Walmsley
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 29, 2003
Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?Sharon Walmsley, Mona Loutfy
Expert Review of Anti-Infective Therapy|February 3, 2007
Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infectionsDarrell Tan, Sharon Walmsley
Expert Opinion on Pharmacotherapy|August 20, 2008
Reassessment of enfuvirtide's role in the management of HIV-1 infectionPatricia Marr, Sharon Walmsley
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
The AIDS Reader|July 4, 2003
Individualized therapy for the treatment-experienced patientSharon Walmsley
Current Opinion in HIV and AIDS|April 18, 2009
Combining protease inhibitors with new drug classes in treatment-experienced patientsSharon Walmsley
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|February 1, 2013
The clinical cost of delays in switching therapySharon Walmsley
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2007
Protease inhibitor-based regimens for HIV therapy: safety and efficacySharon Walmsley
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 27, 2009
Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor classTroy Grennan, Sharon Walmsley
Current Opinion in HIV and AIDS|January 6, 2010
First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approachIsaac Bogoch, Sharon Walmsley
Current Infectious Disease Reports|June 13, 2012
CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and managementLisa Barrett, Sharon Walmsley
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 29, 2003
Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?Sharon Walmsley, Mona Loutfy
Expert Review of Anti-Infective Therapy|February 3, 2007
Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infectionsDarrell Tan, Sharon Walmsley
Expert Opinion on Pharmacotherapy|August 20, 2008
Reassessment of enfuvirtide's role in the management of HIV-1 infectionPatricia Marr, Sharon Walmsley
Pageof 20